Abiopharma

New Form 8-K - Kymera Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0000950170-25-106227 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 6-K - I-Mab Filed: 2025-08-11 AccNo: 0001778016-25-000004 Size: 121 KB

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference

New Form 8-K - Humacyte, Inc. Filed: 2025-08-11 AccNo: 0001818382-25-000122 Size: 366 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 6-K - GSK plc Filed: 2025-08-11 AccNo: 0001654954-25-009314 Size: 49 KB

New Form 424B5 - ASSEMBLY BIOSCIENCES, INC. Filed: 2025-08-11 AccNo: 0001193125-25-177435 Size: 636 KB

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

New Form SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. Filed: 2025-08-11 AccNo: 0000093751-25-000436 Size: 8 KB

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Harvard Bioscience Announces Second Quarter 2025 Financial Results

New Form 10-Q - Compass Therapeutics, Inc. Filed: 2025-08-11 AccNo: 0001171843-25-005261 Size: 5 MB

New Form 8-K - HARVARD BIOSCIENCE INC Filed: 2025-08-11 AccNo: 0001171843-25-005262 Size: 376 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - BIOXYTRAN, INC Filed: 2025-08-11 AccNo: 0001493152-25-011797 Size: 7 MB